FDA starts review of Pfizer, Lilly’s non-opioid painkiller

After years in development, the FDA has started its review of Pfizer and Eli Lilly’s new painkiller tanezumab, one of two remaining drugs in the ill-fated nerve growth factor (NGF) inhibitor class.